Description of the medicine: Reogluman (Rheoglumanum)
The drug, which is a 10% solution of dextran with a molecular weight of 40,000 # 10,000 with the addition of 5% mannitol and 0.9% sodium chloride in water for injection.
Odorless, clear, colorless liquid; pH 4, 0-6.5; relative viscosity at a temperature of + 25 ° C no more than 7, 0.
The drug is considered as a multifunctional blood substitute: it reduces blood viscosity, helps restore blood flow in small capillaries, reduces the aggregation of blood cells, has a detoxifying, osmodiurtic, and also hemodynamic effect.
Rheogluman is used to improve capillary blood flow in diseases accompanied by impaired microcirculation and fluid retention in the body, including traumatic, surgical, cardiogenic, burn shock, arterial and venous blood flow disorders (thrombosis; thrombophlebitis, endarteritis, etc.), for detoxification with burns, peritonitis, pancreatitis, etc.
Reogluman is administered intravenously, drip. Start with the introduction of 5 to 10 drops per minute for 10 to 15 minutes. After the introduction of 5 to 10 drops, and then 30 drops, take breaks for 2 to 3 minutes; if there are no undesirable reactions, proceed to the introduction of the drug at a rate of 40 drops per minute.
Doses and rate of administration are selected individually depending on the indications, the condition of the patient, and urine output.
To maintain the electrolyte balance, it is advisable to introduce solutions containing potassium and sodium simultaneously with reogluman. In the complex therapy of shock, usually from 400 to 800 ml of reogluman is administered for 30-60 minutes (under the control of hemodynamic and urine output indicators).
In cardiovascular surgery, 10 ml / kg of reogluman is administered 30-60 minutes before surgery, 400-500 ml during surgery and daily after surgery for 5-6 days, at a rate of 10 ml / kg.
In acute renal hepatic insufficiency (with preserved filtration capacity), 400 to 800 ml are administered once; then daily (within 3 - 5 days) is applied at the rate of 10 ml / kg for administration, under the control of the water-electrolyte and acid-base state and the blood coagulation system.
Possible complications, precautions and contraindications are the same as when using polyglucin. Rheogluman should not be used with excessive hemodilution (hematocrit below 25 units) and with hemorrhagic diathesis (thrombocytopenia).
Release form: in bottles on 100; 200 and 400 ml.
Storage: at a temperature not lower than +10 and not higher than + 25 C. During transportation, a short-term decrease in storage temperature to - 10 'C is possible.